Drug Profile
RUT 58 60
Alternative Names: RUT58-60Latest Information Update: 11 Mar 2017
Price :
$50
*
At a glance
- Originator Oculus Innovative Sciences
- Developer Pulmatrix
- Class Antibacterials
- Mechanism of Action Angiogenesis inducing agents; Cell membrane inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postoperative infections
Most Recent Events
- 11 Mar 2017 Discontinued - Phase-I/II for Postoperative infections (Adjunctive treatment, Prevention) in USA (Intra-abdominal)
- 05 Dec 2016 Oculus innovative Sciences is now called Sonoma Pharmaceuticals
- 06 Aug 2015 Pulmatrix terminates a phase I/II trial in Post-operative infections in USA (NCT02280395)